Prevention of Asthma Relapse After Discharge From Emergency
PARADE
A Comparison of Budesonide/Formoterol Turbuhaler® 160/4.5 µg 2 Inhalations BID Plus as Needed to Budesonide Turbuhaler® 320 µg 2 Inhalations BID Plus Terbutaline Turbuhaler® 0.4 mg as Needed for the Prevention of Asthma Relapse
2 other identifiers
interventional
600
1 country
20
Brief Summary
The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3 asthma
Started May 2006
Shorter than P25 for phase_3 asthma
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2006
CompletedFirst Submitted
Initial submission to the registry
May 12, 2006
CompletedFirst Posted
Study publicly available on registry
May 16, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2007
CompletedJanuary 24, 2011
January 1, 2011
May 12, 2006
January 21, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time to first asthma relapse
Secondary Outcomes (3)
Mean use of reliever medication
Asthma Control Questionnaire (ACQ) score
Complete AE and SAE collection
Interventions
Eligibility Criteria
You may qualify if:
- years of age
- Presenting at a study emergency department with an asthma exacerbation
You may not qualify if:
- Admission to hospital
- Patients receiving more than 2000 µg/day of beclomethasone equivalent inhaled corticosteroids (1000 µg/day fluticasone or 1600 µg/day budesonide)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (20)
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Lethbridge, Alberta, Canada
Research Site
St. Albert, Alberta, Canada
Research Site
Nanaimo, British Columbia, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Truro, Nova Scotia, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Research Site
Niagara Falls, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Thunder Bay, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Charlottetown, Prince Edward Island, Canada
Research Site
La Malbaie, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Ste-Foy, Quebec, Canada
Research Site
Saskatoon, Saskatchewan, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Gloria Jordana, MD
AstraZeneca
- PRINCIPAL INVESTIGATOR
Brian Rowe, MD
University of Alberta
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
May 12, 2006
First Posted
May 16, 2006
Study Start
May 1, 2006
Study Completion
May 1, 2007
Last Updated
January 24, 2011
Record last verified: 2011-01